Literature DB >> 7491754

Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity.

P Gripon1, J Le Seyec, S Rumin, C Guguen-Guillouzo.   

Abstract

The hepatitis B virus (HBV) envelope contains equimolar amounts of three viral proteins: the major (S), middle, and large (L) polypeptides. Their roles in the adsorption and penetration of the virus have not yet been elucidated. We have used a highly efficient in vitro model that permits reproducible HBV infection to investigate whether N-myristylation, a posttranslational modification of the L protein, was essential for viral infectivity. A point mutation abolishing myristylation was introduced into the HBV genome. Mutant virions were produced by transfecting viral DNA into hepatoma cells and their infectivity was evaluated on primary human hepatocyte cultures. No difference between mutant and wild-type viral RNA production could be observed. Furthermore, intermediate DNA replicative forms were observed in transfected cells demonstrating replication competence of mutant viral genomes. In addition, complete virions were produced in the cell supernatant. However, we found that mutant viral particles contained viral DNA with a reduced mean size, probably corresponding to a larger single-stranded region in the relaxed circular DNA form. We have evidenced the presence of pre-S1, pre-S2, and S epitopes at the outer surface of these virions by using immunoprecipitation with specific monoclonal antibodies. This result confirmed that mutant viruses were normally assembled. By contrast, myristylation-defective mutants completely lost their infectivity for human hepatocytes in primary cultures as shown by the absence of HBs antigen production and viral intermediate replicative forms in hepatocytes. In conclusion, the myristylation of the L protein is not required for the production of Dane-like particles but it is absolutely necessary for HBV infectivity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7491754     DOI: 10.1006/viro.1995.0002

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  74 in total

Review 1.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

Review 2.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

Review 3.  Viral and cellular determinants involved in hepadnaviral entry.

Authors:  Dieter Glebe; Stephan Urban
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

4.  Two potentially important elements of the hepatitis B virus large envelope protein are dispensable for the infectivity of hepatitis delta virus.

Authors:  Severin Gudima; Anja Meier; Roland Dunbrack; John Taylor; Volker Bruss
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

5.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

Review 6.  Molecular biology of hepatitis B virus infection.

Authors:  Christoph Seeger; William S Mason
Journal:  Virology       Date:  2015-03-07       Impact factor: 3.616

7.  Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction.

Authors:  Andreas Schulze; Alexa Schieck; Yi Ni; Walter Mier; Stephan Urban
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

8.  Role of the pre-S2 domain of the large envelope protein in hepatitis B virus assembly and infectivity.

Authors:  J Le Seyec; P Chouteau; I Cannie; C Guguen-Guillouzo; P Gripon
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain.

Authors:  J Le Seyec; P Chouteau; I Cannie; C Guguen-Guillouzo; P Gripon
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

10.  CD1c bypasses lysosomes to present a lipopeptide antigen with 12 amino acids.

Authors:  Ildiko Van Rhijn; David C Young; Annemieke De Jong; Jenny Vazquez; Tan-Yun Cheng; Rahul Talekar; Duarte C Barral; Duarte Barral; Luis León; Michael B Brenner; Joel T Katz; Richard Riese; Ruth M Ruprecht; Peter B O'Connor; Catherine E Costello; Steven A Porcelli; Volker Briken; D Branch Moody
Journal:  J Exp Med       Date:  2009-05-25       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.